{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:51:17Z","timestamp":1740135077285,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmaceutical care for patients with Parkinson\u2019s disease (PD) is complex. Specialized pharmaceutical care provided by a dedicated pharmacy team member (pharmabuddy) for these patients may reduce medication-related problems. The feasibility of this service for PD patients is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the feasibility of a Pharmabuddy Care Service (PCS) for PD patients in primary care pharmacies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pharmabuddies who offered PCS were invited to fill in a questionnaire to evaluate the feasibility of PCS. Patients received a patient questionnaire and were invited for an interview. Patient records provided information on medication-related problems and interventions. Feasibility was evaluated conform four domains of Bowen\u2019s Framework. First, <jats:italic>acceptability<\/jats:italic> included patients\u2019 satisfaction ratings and experiences, Pharmabuddy impression on start and continuation of the service. Second, <jats:italic>demand<\/jats:italic> included use by patients and provision by pharmabuddies. Third, <jats:italic>implementation\/practicality:<\/jats:italic> implementation indicators and barriers and facilitators from patient- and pharmabuddy perspective and fourth <jats:italic>limited efficacy:<\/jats:italic> effect of the PCS on PD symptoms, medication related problems identified and interventions from patient records.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-three (59%) patients completed the questionnaire, 9 were interviewed, 12 (67%) pharmabuddies responded. <jats:italic>Acceptability<\/jats:italic> was high among patients (mean 9.5 (SD 1.3) out of 10), 6 (50%) pharmacies (still) provided PCS. D<jats:italic>emand<\/jats:italic>: 56% of patients had 1\u20132 contact moments, 28% two or more. Ten pharmacies provided up to 14 patients per pharmacy with PCS, one up to 24. <jats:italic>Implementation\/practicality<\/jats:italic>: important barriers were time constraints and perception of other healthcare professionals. Positive reactions from patients encouraged pharmabuddies to carry out their PCS-activities. Patients were positive about pharmabuddy\u2019s listening competency while knowledge could be improved. <jats:italic>Limited efficacy:<\/jats:italic> from patient records, 89 interventions were made in response to 93 (median 3 per patient (range 1\u201316)) medication related problems or questions, with 20 (87%) patients reporting a positive effect from their interaction with a pharmabuddy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study shows PCS is highly appreciated by responding patients and can be feasible for primary care pharmacies. Several implementation issues are still present. Future studies should focus on quantifiable effects of PCS services as well as resource and perception hurdles.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-024-12057-x","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T08:19:33Z","timestamp":1734509973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of a Pharmabuddy Care Service for patients with Parkinson\u2019s disease"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-7195","authenticated-orcid":false,"given":"C. C. M.","family":"Stuijt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-9663","authenticated-orcid":false,"given":"F.","family":"Karapinar-\u00c7arkit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"van de Steeg \u2013 van Gompel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-9514","authenticated-orcid":false,"given":"B. J. F.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Heringa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"12057_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR. The Parkinson pandemic\u2014a call to action. JAMA Neurol. 2018;75:9.","journal-title":"JAMA Neurol"},{"key":"12057_CR2","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.3233\/JPD-202105","volume":"10","author":"E Tenison","year":"2020","unstructured":"Tenison E, Henderson EJ. Multimorbidity and frailty: tackling complexity in Parkinson\u2019s disease. J Parkinsons Dis. 2020;10:S85-91.","journal-title":"J Parkinsons Dis"},{"key":"12057_CR3","unstructured":"Federatie van Medisch Specialisten. Multidisciplinaire richtlijn ziekte van Parkinson. Alphen a\/d Rijn: Van Zuiden Communications; 2020.\u00a0https:\/\/richtlijnendatabase.nl\/richtlijn\/ziekte_van_parkinson\/startpagina_ziekte_van_parkinson.html."},{"key":"12057_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1060028013510898","volume":"48","author":"MN Willson","year":"2014","unstructured":"Willson MN, Greer CL, Weeks DL. Medication regimen complexity and hospital readmission for an adverse drug event. Ann Pharmacother. 2014;48:26\u201332.","journal-title":"Ann Pharmacother"},{"key":"12057_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-017-0904-4","volume":"17","author":"G McLean","year":"2017","unstructured":"McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson\u2019s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17:126.","journal-title":"BMC Neurol."},{"key":"12057_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41598-020-80560-2","volume":"11","author":"N Garin","year":"2021","unstructured":"Garin N, Sole N, Lucas B, Matas L, Moras D, Rodrigo-Troyano A, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11:883.","journal-title":"Sci Rep"},{"key":"12057_CR7","doi-asserted-by":"publisher","first-page":"793361","DOI":"10.3389\/fphar.2021.793361","volume":"12","author":"Z-M Yi","year":"2022","unstructured":"Yi Z-M, Willis S, Zhang Y, Liu N, Tang Q-Y, Zhai S-D. Impact of a collaborative pharmaceutical care service for patients with Parkinson\u2019s disease. Front Pharmacol. 2022;12:793361.","journal-title":"Front Pharmacol"},{"key":"12057_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s11096-011-9526-x","volume":"33","author":"S Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der S, Martus P, Odin P, Schaefer M. Drug-related problems in Parkinson\u2019s disease: the role of community pharmacists in primary care. Int J Clin Pharm. 2011;33:674\u201382.","journal-title":"Int J Clin Pharm"},{"key":"12057_CR9","first-page":"23","volume":"153","author":"KNMP","year":"2018","unstructured":"KNMP. Ministre of Health Care satified about Pharmabuddy results [Minister Bruins tevreden over resultaten Farmabuddy]. Pharmaceutisch Weekblad. 2018;153:23\u201323.","journal-title":"Pharmaceutisch Weekblad"},{"key":"12057_CR10","unstructured":"SIR Institute for Pharmacy Practice and Policy. SIR Farmabuddy Scholingsprogramma [SIR Pharmabuddy educational program]. 2022. https:\/\/sirstevenshof.nl\/product\/farmabuddy-module-parkinson-8-okt-2024\/. Accessed 11 Aug 2024."},{"key":"12057_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","volume":"36","author":"DJ Bowen","year":"2009","unstructured":"Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, et al. How we design feasibility studies. Am J Prev Med. 2009;36:452\u20137.","journal-title":"Am J Prev Med"},{"key":"12057_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcgg.2015.06.004","volume":"6","author":"MA Han","year":"2015","unstructured":"Han MA, Kwon I, Reyes CE, Trejo L, Simmons J, Sarkisian C. Creating a \u201cWellness pathway\u201d between health care providers and community-based organizations to improve the health of older adults. J Clin Gerontol Geriatr. 2015;6:111\u20134.","journal-title":"J Clin Gerontol Geriatr"},{"key":"12057_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1177\/0145721713507114","volume":"39","author":"CW Cen\u00e9","year":"2013","unstructured":"Cen\u00e9 CW, Haymore LB, Ellis D, Whitaker S, Henderson S, Lin F-C, et al. Implementation of the power to prevent diabetes prevention educational curriculum into Rural African American Communities. Diabetes Educ. 2013;39:776\u201385.","journal-title":"Diabetes Educ"},{"key":"12057_CR14","doi-asserted-by":"crossref","unstructured":"van den Bemt PMLA, van der Schrieck-de Loos EM, van der Linden C, Theeuwes AMLJ, Pol AG. Effect of edication reconciliation on unintentional medication discrepancies in acute hospital admissions of elderly adults: a multicenter study. J Am Geriatr Soc. 2013;61(8):1262\u20138.","DOI":"10.1111\/jgs.12380"},{"key":"12057_CR15","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976."},{"key":"12057_CR16","unstructured":"Anja Desomer, Koen van den Heede, Mattanja Triemstra, John Paget, Dolf de Boer, Laurence Kohn, et al. Use of patient-reported outcome and experience measures in patient care and policy. Health Services Research (HSR). 2018. https:\/\/www.nivel.nl\/sites\/default\/files\/bestanden\/KCE_use_of_PROM_PREM.pdf? Accessed 11 Aug 2024."},{"key":"12057_CR17","unstructured":"National Clinical Guideline Centre (UK). Patient Experience in Adult NHS Services: Improving the Experience of Care for People Using Adult NHS Services: Patient Experience in Generic Terms. 2012.\u00a0https:\/\/www.nice.org.uk\/guidance\/cg138."},{"key":"12057_CR18","unstructured":"Nederlands Huisartsen Genootschap, Nederlandse Vereniging voor Klinische Geriatrie, Orde van Medisch Specialisten. Multidisciplinaire Richtlijn Polyfarmacie bij ouderen [multidisciplinary Guideline polypharmacy elderly]. 1st edition. Utrecht: NHG; 2020."},{"key":"12057_CR19","unstructured":"Verantwoording Verkenning Farmabuddyprogramma en Ontwikkeling aanvullende scholing. [accountability exploration Pharmabuddy program and development of additional education]. Leiden; 2020."},{"key":"12057_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/fampra\/cmw115","volume":"34","author":"AOA Plouvier","year":"2017","unstructured":"Plouvier AOA, Olde Hartman TC, Verhulst CEM, Bloem BR, van Weel C, Lagro-Janssen ALM. Parkinson\u2019s disease: patient and general practitioner perspectives on the role of primary care. Fam Pract. 2017;34:227\u201333.","journal-title":"Fam Pract"},{"key":"12057_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12913-018-2841-3","volume":"18","author":"C Vinterflod","year":"2018","unstructured":"Vinterflod C, Gustafsson M, Mattsson S, Gallego G. Physicians\u2019 perspectives on clinical pharmacy services in Northern Sweden: a qualitative study. BMC Health Serv Res. 2018;18:35.","journal-title":"BMC Health Serv Res"},{"key":"12057_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12913-018-3056-3","volume":"18","author":"K Ryan","year":"2018","unstructured":"Ryan K, Patel N, Lau WM, Abu-Elmagd H, Stretch G, Pinney H. Pharmacists in general practice: a qualitative interview case study of stakeholders\u2019 experiences in a West London GP federation. BMC Health Serv Res. 2018;18:234.","journal-title":"BMC Health Serv Res"},{"key":"12057_CR23","unstructured":"Punt voor Parkinson. Center of Excellence on Parkinson\u2019s disease [Punt voor Parkinson]. 2022. www.puntvoorparkinson.nl. Accessed 11 Aug 2024."},{"key":"12057_CR24","doi-asserted-by":"publisher","first-page":"638853","DOI":"10.3389\/fneur.2021.638853","volume":"12","author":"BP van de Warrenburg","year":"2021","unstructured":"van de Warrenburg BP, Tiemessen M, Munneke M, Bloem BR. The architecture of contemporary care networks for rare movement disorders: leveraging the ParkinsonNet experience. Front Neurol. 2021;12:638853.","journal-title":"Front Neurol"},{"key":"12057_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11096-021-01263-w","volume":"43","author":"O Rose","year":"2021","unstructured":"Rose O, Happe S, Huchtemann T, M\u00f6nig C, Ohms M, Schwalbe O, et al. Enhancing medication therapy in Parkinson\u2019s disease by establishing an interprofessional network including pharmacists. Int J Clin Pharm. 2021;43:441\u20138.","journal-title":"Int J Clin Pharm"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-12057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-12057-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-12057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:10:41Z","timestamp":1734513041000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-12057-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12057"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-12057-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"type":"electronic","value":"1472-6963"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Review Board of the University Medical Centre Utrecht concluded that this study did not require WMO approval, because it is not about clinical research with human participants as intended by the Dutch Medical Research Involving Human Subjects Act. Therefore, Human Ethics and Consent to Participate declarations is not applicable. Consent to Participate declaration: patients gave informed consent for the interviews and they were also asked to consent the recording of the interviews. Questionnaires and patient records were anonymized and stored on protected servers. The authors declare all methods were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1560"}}